“Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is headquartered in Radnor, Pennsylvania. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, Twitter and Bluesky”
Mineralys is a fully remote company.
Executive Director, Clinical Development
The Executive Director, Clinical Development will serve as the clinical lead for development program(s) and play a critical role in advancing pivotal studies, regulatory strategy, and submission readiness. This physician leader will provide medical and scientific oversight across the program lifecycle, from protocol design and study execution through data interpretation, regulatory interactions, and launch preparation.
This role requires a hands-on clinical development leader who thrives in a fast-paced biotech environment and can partner cross-functionally to drive high-quality execution with urgency.
Key Responsibilities:
Clinical Development Leadership
Medical Monitoring / Safety Oversight
Regulatory / Submission Support
Scientific / Cross-Functional Leadership
Team / Culture Leadership
Experience and Qualifications:
These positions are eligible for standard Company benefits including medical, dental, vision, time off and 401K, as well as participating in Mineralys incentive plans are contingent on achievement of personal and company performance. Actual compensation may vary from posted hiring range based on geographic location, work experience, education, and/or skill level.
US Salary Range: $340,000 - $370,000
#LI-REMOTE
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to treat hypertension and related comorbidities including chronic kidney disease, obstructive sleep apnea, and other diseases driven by dysregulated aldosterone. The company's initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is advancing this therapeutic approach through clinical development to address unmet medical needs in cardiovascular and renal disease management.